

Nelson L Michael

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/422436/nelson-l-michael-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142 papers	13,825 citations	50 h-index	117 g-index
152 ext. papers	16,792 ext. citations	15.8 avg, IF	5.58 L-index

#	Paper	IF	Citations
142	Neurocognitive impact of Zika virus infection in adult rhesus macaques.. <i>Journal of Neuroinflammation</i> , 2022 , 19, 40	10.1	0
141	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022 , 14,	17.5	9
140	HIV-1 infections with multiple founders associate with the development of neutralization breadth.. <i>PLoS Pathogens</i> , 2022 , 18, e1010369	7.6	1
139	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022 , 10, 717	5.3	1
138	Disclosure of Same-Sex Sexual Practices to Family and Healthcare Providers by Men Who Have Sex with Men and Transgender Women in Nigeria. <i>Archives of Sexual Behavior</i> , 2021 , 50, 1665-1676	3.5	6
137	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.. <i>Cell Reports</i> , 2021 , 37, 110143	10.6	16
136	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. <i>Human Immunology</i> , 2021 , 83, 53-53	2.3	0
135	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2021 , JVI0159921	6.6	2
134	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021 , 6, 129	9.5	8
133	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , 2021 , 22, 1503-1514	19.1	12
132	Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates 2021 ,		12
131	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021 , 29, 564-578.e9	23.4	8
130	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. <i>Frontiers in Immunology</i> , 2021 , 12, 682120	8.4	3
129	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity 2021 ,		13
128	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. <i>PLoS Pathogens</i> , 2021 , 17, e1009673	7.6	2
127	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021 , 7, veab057	3.7	1
126	Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021 , 12, 640190	8.4	2

125	Factors influencing estimates of HIV-1 infection timing using BEAST. <i>PLoS Computational Biology</i> , 2021 , 17, e1008537	5	2
124	A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. <i>Lancet HIV</i> , 2021 , 8, e449-e452	7.8	3
123	Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort. <i>AIDS Research and Therapy</i> , 2021 , 18, 52	3	0
122	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. <i>Journal of Virology</i> , 2021 , 95, e0079721	6.6	2
121	SARS-CoV-2 Variants in Patients with Immunosuppression. <i>New England Journal of Medicine</i> , 2021 , 385, 562-566	59.2	92
120	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. <i>ELife</i> , 2021 , 10,	8.9	2
119	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	12
118	Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. <i>EBioMedicine</i> , 2021 , 63, 103175	8.8	1
117	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses.. <i>Npj Vaccines</i> , 2021 , 6, 151	9.5	6
116	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , 2020 , 20, 1061-1070	25.5	15
115	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020 , 26, 498-501	50.5	17
114	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	31
113	CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir. <i>Journal of Immunology</i> , 2020 , 205, 699-707	5.3	4
112	Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. <i>New England Journal of Medicine</i> , 2020 , 383, e63	59.2	46
111	Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. <i>Nature Communications</i> , 2020 , 11, 272	17.4	18
110	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020 , 5,	9.9	4
109	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , 2020 , 5,	9.9	1
108	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2845-2858	15.9	16

107	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3299-3304	15.9	9
106	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. <i>Nature Medicine</i> , 2020 , 26, 228-235	50.5	30
105	A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein 2020 ,		23
104	Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa429	1	
103	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 23652-23662	11.5	133
102	Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection. <i>Cells</i> , 2019 , 8,	7.9	6
101	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	15
100	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	24
99	Time to change the paradigm: limited condom and lubricant use among Nigerian men who have sex with men and transgender women despite availability and counseling. <i>Annals of Epidemiology</i> , 2019 , 31, 11-19.e3	6.4	12
98	The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes. <i>PLoS Computational Biology</i> , 2019 , 15, e1007056	5	12
97	Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. <i>Cells</i> , 2019 , 8,	7.9	3
96	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019 , 6, e297-e306	7.8	46
95	Expansion of Stem Cell-Like CD4 Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression. <i>Journal of Virology</i> , 2019 , 93,	6.6	5
94	Modeling HIV-1 Latency Using Primary CD4 T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Journal of Virology</i> , 2019 , 93,	6.6	7
93	Next-generation sequencing of HIV-1 single genome amplicons. <i>Biomolecular Detection and Quantification</i> , 2019 , 17, 100080	12	2
92	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019 , 10, 863	17.4	17
91	Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. <i>Journal of Clinical Investigation</i> , 2019 , 129, 3361-3373	15.9	35
90	Simplified steps to heterologous prime-boost HIV vaccine development?. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4572-4573	15.9	1

89	Terminal Effector CD8 T Cells Defined by an IKZF2IL-7R Transcriptional Signature Express FcBIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Immunology</i> , 2019 , 203, 2210-2221	5.3	13
88	Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 16, 206-216	6	13
87	Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. <i>Nature Communications</i> , 2018 , 9, 1212	17.4	24
86	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018 , 218, 633-644	7	23
85	Elevated expression impairs HIV control through inhibition of NKG2A-expressing cells. <i>Science</i> , 2018 , 359, 86-90	33.3	89
84	Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 78, 348-355	3.1	6
83	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018 , 392, 232-243	40	170
82	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. <i>Journal of Immunological Methods</i> , 2018 , 462, 74-82	2.5	11
81	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. <i>Nature Medicine</i> , 2018 , 24, 923-926	50.5	146
80	Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1903-1912	15.9	30
79	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018 , 14, e1006888	7.6	18
78	Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. <i>Lancet, The</i> , 2018 , 391, 563-571	40	126
77	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. <i>PLoS ONE</i> , 2018 , 13, e0194266	3.7	9
76	Full-length next-generation sequencing of HLA class I and II genes in a cohort from Thailand. <i>Human Immunology</i> , 2018 , 79, 773-780	2.3	8
75	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV,the</i> , 2018 , 5, e366-e378	7.8	62
74	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017 , 376, 330-341	59.2	248
73	Prospects for a Zika Virus Vaccine. <i>Immunity</i> , 2017 , 46, 176-182	32.3	69
72	Delayed differentiation of potent effector CD8 T cells reducing viremia and reservoir seeding in acute HIV infection. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	58

71	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017 , 215, 1255-1263	7	45
70	Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant. <i>Npj Vaccines</i> , 2017 , 2, 13	9.5	25
69	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017 , 8, 15711	17.4	94
68	Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-STING-Type I IFN Pathway and AIM2 Sensor. <i>Journal of Immunology</i> , 2017 , 199, 3293-3305	5.3	21
67	Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21652	5.4	11
66	Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques. <i>PLoS Pathogens</i> , 2017 , 13, e1006487	7.6	97
65	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017 , 13, e1006510	7.6	33
64	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	80
63	Human Primary Macrophages Derived from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection. <i>Frontiers in Immunology</i> , 2017 , 8, 1352	8.4	7
62	Clinical trial design: The nobility of randomization. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	1
61	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017 , 12, e0180720	3.7	42
60	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017 , 13, e1006182	7.6	30
59	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016 , 2, 43-48	2.8	52
58	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016 , 540, 284-287	50.4	183
57	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016 , 22, 762-70	50.5	147
56	Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: the importance of HIV-1 envelope V1V2 region. <i>Journal of Leukocyte Biology</i> , 2016 , 99, 1089-106	6.5	18
55	Vaccine protection against Zika virus from Brazil. <i>Nature</i> , 2016 , 536, 474-8	50.4	383
54	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. <i>Journal of Virology</i> , 2016 , 90, 4005-4016	6.6	16

53	Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations. <i>PLoS ONE</i> , 2016 , 11, e0146196	3.7	5
52	Sequential Dysfunction and Progressive Depletion of <i>Candida albicans</i> -Specific CD4 T Cell Response in HIV-1 Infection. <i>PLoS Pathogens</i> , 2016 , 12, e1005663	7.6	19
51	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016 , 2, 43-48	2.8	37
50	Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. <i>Journal of the International AIDS Society</i> , 2016 , 19, 211634	5.4	27
49	Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. <i>New England Journal of Medicine</i> , 2016 , 374, 2120-30	59.2	151
48	HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. <i>EBioMedicine</i> , 2016 , 11, 68-72	8.8	139
47	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , 2016 , 353, 1129-32	33.3	386
46	Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. <i>PLoS Computational Biology</i> , 2015 , 11, e1003973	5	44
45	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015 , 7, 296ra112	17.5	38
44	Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. <i>Journal of Virology</i> , 2015 , 89, 7494-505	6.6	56
43	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015 , 163, 988-98	56.2	230
42	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015 , 21, 1139-41	50.5	29
41	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015 , 1, 116-122	2.8	43
40	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015 , 33, 610-6	44.5	165
39	Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to $\alpha 4 \beta 7$ Integrin Receptor. <i>PLoS ONE</i> , 2015 , 10, e0143895	3.7	31
38	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015 , 1, 116-122	2.8	30
37	Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 13439-44	11.5	40
36	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , 2014 , 512, 74-7	50.4	403

35	Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. <i>Journal of Virology</i> , 2014 , 88, 12385-96	6.6	144
34	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. <i>Immunogenetics</i> , 2014 , 66, 299-310	3.2	12
33	Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. <i>Journal of Virological Methods</i> , 2014 , 205, 7-16	2.6	4
32	Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. <i>PLoS Pathogens</i> , 2014 , 10, e1004543	7.6	171
31	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. <i>EBioMedicine</i> , 2014 , 1, 37-45	8.8	40
30	The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. <i>Journal of Virology</i> , 2014 , 88, 1809-14	6.6	53
29	HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. <i>Journal of Virology</i> , 2014 , 88, 7715-26	6.6	140
28	Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. <i>Immunity</i> , 2014 , 41, 909-18	32.3	50
27	Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. <i>Science Translational Medicine</i> , 2014 , 6, 228ra39	17.5	336
26	Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. <i>Science Translational Medicine</i> , 2014 , 6, 228ra38	17.5	290
25	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3879-90	15.9	86
24	Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. <i>PLoS ONE</i> , 2014 , 9, e87572	3.7	209
23	A novel acute HIV infection staging system based on 4th generation immunoassay. <i>Retrovirology</i> , 2013 , 10, 56	3.6	71
22	Nautilus: a bioinformatics package for the analysis of HIV type 1 targeted deep sequencing data. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 1361-4	1.6	6
21	Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. <i>Cell</i> , 2013 , 155, 531-9	56.2	268
20	Influence of HLA-C expression level on HIV control. <i>Science</i> , 2013 , 340, 87-91	33.3	277
19	Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. <i>Immunity</i> , 2013 , 38, 176-86	32.3	319
18	Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. <i>Journal of Virology</i> , 2013 , 87, 1554-68	6.6	85

17	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 9019-24	11.5	301
16	Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection. <i>Blood</i> , 2013 , 121, 1136-44	2.2	30
15	Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. <i>PLoS ONE</i> , 2013 , 8, e75665	3.7	189
14	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. <i>Lancet Infectious Diseases</i> , 2012 , 12, 531-7	25.5	162
13	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012 , 490, 417-20	50.4	342
12	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. <i>Nature</i> , 2012 , 482, 89-93	50.4	391
11	Immune-correlates analysis of an HIV-1 vaccine efficacy trial. <i>New England Journal of Medicine</i> , 2012 , 366, 1275-86	59.2	1400
10	Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. <i>Journal of Infectious Diseases</i> , 2012 , 206, 431-41	7	229
9	Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. <i>Journal of Virology</i> , 2012 , 86, 11521-32	6.6	294
8	The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1444-57	1.6	159
7	Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. <i>PLoS ONE</i> , 2012 , 7, e33948	3.7	242
6	Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. <i>PLoS ONE</i> , 2011 , 6, e18779	3.7	33
5	Quality monitoring of HIV-1-infected and uninfected peripheral blood mononuclear cell samples in a resource-limited setting. <i>Vaccine Journal</i> , 2010 , 17, 910-8		18
4	Host determinants of HIV-1 control in African Americans. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1141-9		125
3	Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. <i>New England Journal of Medicine</i> , 2009 , 361, 2209-20	59.2	2298
2	A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains		8
1	A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells		5